Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome (Q44872965)

7 December 2017

title

Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome (English)

1 reference

7 December 2017

1 reference

Schrader C

1 reference

7 December 2017

Meusers P

1 reference

7 December 2017

Brittinger G

1 reference

7 December 2017

Teymoortash A

1 reference

7 December 2017

Siebmann JU

1 reference

7 December 2017

Janssen D

1 reference

7 December 2017

Parwaresch R

1 reference

7 December 2017

Tiemann M

1 reference

7 December 2017

publication date

1 July 2004

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

page(s)

1200-1206

1 reference

Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes).

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Mantle-cell lymphoma: a population-based clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

DNA gyrase: an enzyme that introduces superhelical turns into DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Culprit and victim -- DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: studies using the inhibitor 4'-demethylepipodophyllotoxin 9-(4,6-O-thenylidene-beta-D-glucopyranoside).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Immunohistochemical Staining for DNA Topoisomerase II in Non-Hodgkin’s Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Evaluation of DNA topoisomerase IIalpha expression provides independent prognostic information in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

[Moist autoclaving. A simplified method for antigen unmasking]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

bc1-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403387

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403387

1 reference

Dimensions Publication ID

7 December 2017

1000616408

0 references

1 reference